180 Life Sciences (ATNF) Competitors $2.53 +0.13 (+5.42%) As of 09/23/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. ALGS, DRRX, CELU, NRXP, GANX, DTIL, PRLD, ICCC, GNTA, and CUEShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Aligos Therapeutics (ALGS), DURECT (DRRX), Celularity (CELU), NRx Pharmaceuticals (NRXP), Gain Therapeutics (GANX), Precision BioSciences (DTIL), Prelude Therapeutics (PRLD), ImmuCell (ICCC), Genenta Science (GNTA), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Aligos Therapeutics DURECT Celularity NRx Pharmaceuticals Gain Therapeutics Precision BioSciences Prelude Therapeutics ImmuCell Genenta Science Cue Biopharma 180 Life Sciences (NASDAQ:ATNF) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Do analysts prefer ATNF or ALGS? Aligos Therapeutics has a consensus target price of $50.00, indicating a potential upside of 365.12%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ATNF or ALGS? 180 Life Sciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ATNF or ALGS? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 38.2% of 180 Life Sciences shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, ATNF or ALGS? 180 Life Sciences has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$15.07-0.17Aligos Therapeutics$3.94M16.78-$131.21M-$19.79-0.54 Is ATNF or ALGS more profitable? 180 Life Sciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -141.25% -80.77% Aligos Therapeutics -2,337.24%-22.41%-12.09% Does the media prefer ATNF or ALGS? In the previous week, Aligos Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Aligos Therapeutics Neutral SummaryAligos Therapeutics beats 180 Life Sciences on 9 of the 14 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.28M$3.11B$5.74B$10.35BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-0.1720.9076.3526.43Price / SalesN/A253.84466.9091.03Price / CashN/A46.3537.4661.85Price / Book0.879.8313.186.39Net Income-$6.17M-$52.73M$3.29B$271.22M7 Day Performance9.52%4.84%2.50%2.78%1 Month Performance-23.33%6.37%4.59%7.35%1 Year Performance35.29%19.14%73.81%29.74% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$2.53+5.4%N/A+29.0%$15.28MN/A-0.177Gap UpALGSAligos Therapeutics3.378 of 5 stars$9.53-1.4%$50.00+424.7%+26.5%$59.48M$3.94M-0.4890Gap UpDRRXDURECT1.6403 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080CELUCelularity1.292 of 5 stars$2.12-4.5%$6.00+183.0%-24.3%$59.26M$54.22M-0.67220NRXPNRx Pharmaceuticals3.2852 of 5 stars$2.87-3.4%$34.50+1,102.1%+72.7%$58.83MN/A-1.282News CoveragePositive NewsGap UpGANXGain Therapeutics2.7088 of 5 stars$1.74+10.1%$8.00+359.8%+12.9%$56.80M$50K-2.7620News CoverageDTILPrecision BioSciences3.9627 of 5 stars$4.86+1.7%$47.00+867.1%-48.0%$56.34M$68.70M-0.55200PRLDPrelude Therapeutics3.0772 of 5 stars$1.01+2.6%$4.00+296.0%-56.5%$55.74M$7M-0.62120News CoverageAnalyst ForecastICCCImmuCell1.0099 of 5 stars$6.25+4.9%N/A+71.4%$53.91M$26.49M32.9070News CoveragePositive NewsGap DownGNTAGenenta Science2.5807 of 5 stars$2.97+3.7%$25.00+742.9%-20.5%$52.31MN/A0.007Positive NewsCUECue Biopharma1.36 of 5 stars$0.70+4.7%N/A+48.1%$51.65M$9.29M-1.2660 Related Companies and Tools Related Companies ALGS Competitors DRRX Competitors CELU Competitors NRXP Competitors GANX Competitors DTIL Competitors PRLD Competitors ICCC Competitors GNTA Competitors CUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNF Stock Alerts